MA32460B1 - Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases - Google Patents

Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases

Info

Publication number
MA32460B1
MA32460B1 MA33499A MA33499A MA32460B1 MA 32460 B1 MA32460 B1 MA 32460B1 MA 33499 A MA33499 A MA 33499A MA 33499 A MA33499 A MA 33499A MA 32460 B1 MA32460 B1 MA 32460B1
Authority
MA
Morocco
Prior art keywords
substituted
optionally
heterocyclic
branched
straight
Prior art date
Application number
MA33499A
Other languages
Arabic (ar)
English (en)
Inventor
Olivier Bedel
Christopher Arendt
Didier Babin
Thierry Gouyon
Mikhail Levit
Serge Mignani
Neil Moorcroft
David Papin
Ronghua Li
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32460B1 publication Critical patent/MA32460B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nouvelles azacarbolines de formule :(i) dans laquelle : r3, r4 représentent indépendamment l'un de l'autre h;hal; cf3; oxy substituée; alkoxy éventuellement substitué; amino éventuellement substitué; carbonyle substitué; carboxyle éventuellement substitué; amide éventuellement substitué; soufre tels que les sulfures, sulfoxides ou sulfones éventuellement substitués;c1-c10 alkyle linéaire, ramifié ou cyclique comportant éventuellement un hétéroatome éventuellement substitué;c2-c7 alkenyle linéaire, ramifié ou cyclique éventuellement substitué; c2-c6 alkynyle linéaire ou ramifié éventuellement substitué; aryle ou hétéroaryle éventuellement substitué;hétérocycloalkyle éventuellement substitué; r6 représente hétéroaryle, c(o)nr1ar1b, hétérocycloalkyle ou -c(o)hétérocycloalkyle tous éventuellement substitués; à l'état de base ou de sel d'addition à un acide. Utilisation en thérapeutique pour le traitement du cancer et procédés de synthèse.
MA33499A 2008-06-12 2011-01-07 Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases MA32460B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0803262 2008-06-12
PCT/FR2009/051100 WO2009150381A2 (fr) 2008-06-12 2009-06-11 Derives d'azacarbolines, leur preparation et leur utilisation therapeutique

Publications (1)

Publication Number Publication Date
MA32460B1 true MA32460B1 (fr) 2011-07-03

Family

ID=40445526

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33499A MA32460B1 (fr) 2008-06-12 2011-01-07 Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases

Country Status (26)

Country Link
US (1) US20110178053A1 (fr)
EP (1) EP2303882A2 (fr)
JP (1) JP2011522867A (fr)
KR (1) KR20110016998A (fr)
CN (1) CN102124007A (fr)
AR (1) AR072084A1 (fr)
AU (1) AU2009259114B2 (fr)
BR (1) BRPI0915204A2 (fr)
CA (1) CA2725093A1 (fr)
CO (1) CO6280536A2 (fr)
CR (1) CR11814A (fr)
DO (1) DOP2010000366A (fr)
EA (1) EA018945B1 (fr)
EC (1) ECSP10010670A (fr)
IL (1) IL209840A0 (fr)
MA (1) MA32460B1 (fr)
MX (1) MX2010013699A (fr)
NI (1) NI201000210A (fr)
NZ (1) NZ589839A (fr)
PE (1) PE20110122A1 (fr)
SV (1) SV2010003754A (fr)
TW (1) TW201002711A (fr)
UA (1) UA101668C2 (fr)
UY (1) UY31895A (fr)
WO (1) WO2009150381A2 (fr)
ZA (1) ZA201008387B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2706059A1 (fr) 2008-06-11 2014-03-12 Genentech, Inc. Diazacarbazoles et procédés d'utilisation
NZ589532A (en) 2008-06-12 2012-02-24 Janssen Pharmaceutica Nv Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
AU2009342734A1 (en) * 2009-03-24 2011-10-13 Sanofi 9H-pyrrolo[2,3-b: 5,4-c'] dipyridine azacarboline derivatives, preparation thereof, and therapeutic use thereof
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
CN105377851B (zh) * 2013-03-11 2018-07-20 密执安州立大学董事会 Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
CN110198941B (zh) * 2017-01-25 2021-09-28 江苏豪森药业集团有限公司 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
MX2020001531A (es) * 2017-08-07 2020-03-20 Biocad Joint Stock Co Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
US11485734B2 (en) 2018-10-02 2022-11-01 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2706059A1 (fr) * 2008-06-11 2014-03-12 Genentech, Inc. Diazacarbazoles et procédés d'utilisation

Also Published As

Publication number Publication date
WO2009150381A2 (fr) 2009-12-17
UY31895A (es) 2010-01-29
AU2009259114A1 (en) 2009-12-17
EP2303882A2 (fr) 2011-04-06
CR11814A (es) 2011-01-10
CO6280536A2 (es) 2011-05-20
US20110178053A1 (en) 2011-07-21
SV2010003754A (es) 2011-03-15
UA101668C2 (ru) 2013-04-25
BRPI0915204A2 (pt) 2019-01-15
TW201002711A (en) 2010-01-16
IL209840A0 (en) 2011-02-28
AU2009259114B2 (en) 2013-05-23
NI201000210A (es) 2011-05-09
CA2725093A1 (fr) 2009-12-17
AR072084A1 (es) 2010-08-04
NZ589839A (en) 2012-07-27
KR20110016998A (ko) 2011-02-18
EA201170002A1 (ru) 2011-08-30
MX2010013699A (es) 2011-02-23
ECSP10010670A (es) 2011-01-31
EA018945B1 (ru) 2013-11-29
CN102124007A (zh) 2011-07-13
DOP2010000366A (es) 2010-12-31
ZA201008387B (en) 2012-02-29
JP2011522867A (ja) 2011-08-04
WO2009150381A3 (fr) 2010-02-18
PE20110122A1 (es) 2011-03-07

Similar Documents

Publication Publication Date Title
MA32460B1 (fr) Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
CY1118340T1 (el) Αναστολεις κινασης
ATE540037T1 (de) Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
NZ607638A (en) Novel compounds and compositions for the inhibition of nampt
MY177250A (en) Novel nicotinamide derivative or salt thereof
PE20091819A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
RS54506B1 (en) PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS
NZ607794A (en) N-acylsulfonamide apoptosis promoters
SMP201100019B (it) Composti organici
EA201200318A1 (ru) Гетероциклические оксимы
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
DK2840080T3 (da) Nitrogenholdig heterocyklisk forbindelse eller salt deraf
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
BR112012017123A2 (pt) composto de n-(1h-indazol-4-il)imidazo [1,2-a]piridina-3-carboxamida como inibidores de cfms
EA201391629A1 (ru) Ингибиторы цсж-1r для лечения опухолей головного мозга
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
EA201491820A1 (ru) Новые тиенопиримидиновые производные, способы их получения и их терапевтические применения